Streetbeat News

Products Services

PTIX

Protagenic Therapeutics has initiated a Phase I/IIa clinical trial for PT00114, a synthetic version of the naturally occurring brain peptide TCAP. The trial aims to evaluate the therapeutic potential of PT00114 in treating neuro-psychiatric conditions, including depression, anxiety, and PTSD. The study will recruit 56 subjects and will be managed by Axiom Real-Time Metrics.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 12:20 pm

ENSC

Ensysce Biosciences (NASDAQ:ENSC) has completed the Site Initiation Visit (SIV) for the PF614-201 study, a critical step towards Phase 3. The study aims to evaluate the time of onset for PF614, a chemically modified opioid product. The trial results are expected by the end of 2023.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 12:20 pm

NEGG

Newegg Commerce, Inc. (NASDAQ:NEGG) has launched a GPU Trade-In Program, allowing customers to trade in an eligible GPU device for credit towards the purchase of a new graphics card. The program aims to facilitate cost-effective PC upgrades and limit electronic waste. The trade-in process involves eligibility confirmation, preliminary offer and shipping to Newegg, and evaluation and credit disbursement.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 12:19 pm

MOTS

Motus GI has submitted a Special 510(K) to the FDA for market clearance of its Pure-Vu Gen 4 Gastro and Colon. The FDA usually reviews a Special 510(K) within 30 days of receipt.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 12:19 pm

PBLA

Panbela Therapeutics (NASDAQ:PBLA) has announced the issuance of a new patent in China for a novel process for the production of SBP-101, a lead investigational product. The patent, developed in collaboration with Syngene International Ltd., reduces the number of synthetic steps from seventeen to six, making the production more scalable, efficient, and cost-effective. The patent is valid until 2039 and is expected to improve the overall competitiveness of SBP-101 in the market.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 12:19 pm

BLNK

Blink Charging has announced an agreement to integrate over 4,000 of its EV charging locations onto the Parkopedia platform in North America. This partnership will increase the visibility and accessibility of Blink's charging stations.

Portfolio Pulse from Bill Haddad

September 26, 2023 | 12:17 pm

MRNA

VGK

The European Union is in discussions with Moderna Inc. for a new deal to secure additional doses of its COVID-19 vaccine. The deal is expected to include the purchase of new versions of the vaccine that could be more effective against variants of the virus.

Portfolio Pulse from Charles Gross

September 26, 2023 | 12:17 pm

AKBA

Australia's Therapeutic Goods Administration has approved Akebia Therapeutics' Vafseo (Vadadustat) for anemia associated with chronic kidney disease in adults on chronic maintenance dialysis.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 12:15 pm

CRL

Charles River Laboratories International, Inc. (NYSE:CRL) has launched its lentiviral vector (LVV) manufacturing platform, Lentivation™, which can reduce LVV manufacturing timelines for gene and gene-modified cell therapies by up to 60 percent. This translates to fewer than seven months compared to traditional manufacturing workflows. The platform will be presented during the BioInsight's Expert Roundtable on September 27, 2023.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 12:15 pm

VCNX

Vaccinex, Inc. (NASDAQ:VCNX) has reported novel findings for its lead product, pepinemab, at two medical conferences. The findings suggest that pepinemab has the potential to prevent decline in brain metabolic activity and slow cognitive decline in neurodegenerative diseases like Huntington's and Alzheimer's. Additionally, pepinemab in combination with a checkpoint inhibitor has shown potential to induce formation of lymphoid structures in tumors, improving outcomes in head and neck cancer.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 12:14 pm